Archives

A federal court and an appellate court ruled that Pfizer’s attempts to help patients with copay and deductible payments violates the AKS even if Pfizer acted with good intent.

Physicians and healthcare companies such as pharmaceutical companies need to understand when remuneration violates the Anti-Kickback Statute. Some safe harbors may apply.

OIG advisory opinion provides that payments for travel, lodging, and other costs related to a drug infusion treatment should not violate the federal Anti-Kickback Statute